Key result
Transcatheter aortic valve implantation with the novel self-expanding NVT Allegra bioprosthesis achieved 95.2% procedural success and 85.7% device success in 21 high-risk patients.
Why the study?
Is transcatheter aortic valve implantation with the novel self-expanding NVT Allegra bioprosthesis feasible and safe in elderly patients with severe aortic stenosis at prohibitive surgical risk?
Observational (n=21)
Yes
Is transcatheter aortic valve implantation with the novel self-expanding NVT Allegra bioprosthesis feasible and safe in elderly patients with severe aortic stenosis at prohibitive surgical risk?
The first-in-human experience with the NVT Allegra self-expanding TAVI system demonstrated high procedural success and favorable short-term hemodynamics in high-risk patients with severe aortic stenosis.
Authors
No takes yet. Share an insight, caveat, or question.
Supports feasibility of NVT Allegra TAVI in high-risk aortic stenosis; leaves open safety and efficacy confirmation in larger trials.
Wenaweser et al. (2016) conducted an observational in symptomatic severe aortic stenosis (n=21). NVT Allegra transcatheter heart valve system was evaluated on Procedural success. Transcatheter aortic valve implantation with the novel self-expanding NVT Allegra bioprosthesis achieved 95.2% procedural success and 85.7% device success in 21 high-risk patients.